ICYMI, some of this week’s featured content includes a new podcast episode, as well as articles on treating skin conditions in Asian patients, the newest FDFA approvals, acne treatment updates from AAD, and more.
Emmy Graber, MD, presented the updates in acne and rosacea treatments at the SCALE Acne and Rosacea update on June 9, 2021.
The B-SIMPLE4 phase 3 trial achieved positive efficacy results for the treatment of molluscum contagiosum.
A higher prevalence of vitamin D deficiency in people of color may be contributing to a higher burden of COVID-19 in minority populations. Dermatologists are encouraged to address vitamin D status in patients and recommend supplementation, which might have other health benefits.
Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases.
Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/GSM Expert Resource Group, tips and resources for maintaining your mental health as a gender and sexual minority.
American Academy of Dermatology’s updated guidelines on acne will cover dermatology’s hottest issues, from dosing and monitoring established medications to exploring new antibiotics and addressing antibiotic stewardship.
IDP-126, an acne vulgaris treatment for patients ages 9 and older, met all of its endpoints in a 12-week phase 3 study.
Nutrafol launches a new nutraceutical, called Postpartum, aimed at helping women’s hair health post-pregnancy.
This episode dives into how health care policy impacts gender and sexual minority patients, including exploring the Affordable Care Act (ACA) and Medicaid expansion, and identifying state and federal nondiscrimination protections that help defend equal access to health care for this patient population.
Mallinckrodt announces the FDA approval of StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns.
Hugel America announces the FDA has approved the BLA application for letibotulinumtoxinA as a treatment for glabellar lines in adult patients.
Experts present detailed guidelines on how to diagnose and treat common skin diseases and conditions in the Asian American population.